News
AMGN
468.11
+0.62%
2.88
Regeneron Pharmaceuticals Inc. Stock Climbs 4.7%, Outperforms Peers
Dow Jones · 10h ago
Democratic senators probe gifts to RFK Jr. from large donor to his presidential campaign
Seeking Alpha · 11h ago
What Does Amgen (AMGN) FDA Warning Mean For Investors?
Simply Wall St · 15h ago
Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears
Benzinga · 16h ago
Want $7,000 in Passive Income? Buy These 3 Dividend Stocks Today
24/7 Wall St. · 17h ago
Amgen slips after late-stage trial data for Sjögren's disease therapy
Seeking Alpha · 18h ago
Amgen's Dazodalibep Shows Phase 3 Success In Sjögren's Disease With No Approved Treatments Available
NASDAQ · 18h ago
Amgen reports results from Phase 3 OASIZ-301 study of dazodalibep
TipRanks · 18h ago
Amgen Says Dazodalibep Met Primary Endpoint At Week 48
Benzinga · 18h ago
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
PR Newswire · 18h ago
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?
24/7 Wall St. · 1d ago
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
24/7 Wall St. · 1d ago
Sino Biopharmaceutical Stock Climbs 1.6% in Hong Kong
Dow Jones · 1d ago
Amgen Highlights Repatha's Cost-Effectiveness, Long-Term Cardiovascular Benefits
NASDAQ · 2d ago
Trump's Plan to Lower Drug Prices in U.S. Is Leading to Fewer New Drugs in Europe
The Wall Street Journal · 2d ago
Amgen’s Repatha shows cost-effectiveness in cardiovascular study
TipRanks · 2d ago
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM
PR Newswire · 2d ago
Is Amgen (AMGN) Expensive On Strong Q3 Results And Pipeline Progress?
Simply Wall St · 2d ago
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Benzinga · 2d ago
Amgen (AMGN) Gets a Buy from Piper Sandler
TipRanks · 2d ago
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.